Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs SSR Mining Inc. Common Stock (SSRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs SSR Mining Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while SSR Mining Inc. Common Stock trades at $31.4 (market cap $6.26B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and SSR Mining Inc. Common Stock pays a 0.1% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and SSR Mining Inc. Common Stock for 1 Days on average.
| KYMR | SSRM | |
|---|---|---|
Market Cap | $8.87B | $6.26B |
Volume | 779,107 | 4,191,911 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $39.21 |
52-Week Low | $55.80 | $19.48 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $8.26B | $4.43B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SSR Mining (SSRM) trades at $33.09, down 6.63% amid recent volatility, yet maintains strong fundamentals with a P/E of 12.44 and net income margin of 12.3%. The company recently announced the $464 million acquisition of Roxmore Resources, which could add 170,000 ounces of annual gold production. Technical indicators show a bullish trend with support at $34-$35, while earnings have beaten expectations in two of the last three quarters.
The outlook remains positive with a consensus price target of $42.67 (29% upside), driven by strategic acquisitions and Americas-focused growth. Risks include execution of the Roxmore integration and gold price sensitivity. Analysts are bullish (73% buy ratings), citing the company's debt-free balance sheet and $1.8 billion cash position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About SSR Mining Inc. Common Stock
SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →
